
Dr Olga Kondrashova is an NHMRC Emerging Leadership Fellow and leads the Molecular Oncology group at QIMR Berghofer. With over nine years of post-PhD experience, she has made significant contributions to cancer genomics and precision oncology, particularly in understanding treatment responses and resistance to PARP inhibitors. Her research has identified key resistance mechanisms, including secondary mutations in RAD51C/D and BRCA1/RAD51C methylation, and has been published in leading journals such as Cancer Discovery, Nature Communications and Genome Medicine. Her team applies advanced genomic, bioinformatic, and machine learning approaches to find novel biomarkers and guide cancer treatment strategies.


